These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6625552)

  • 1. Minimal inhibitory concentrations of lucknomycin, a new polyenic derivative, for Candida and Aspergillus spp.
    Martínez-Quesada J; Torres-Rodriguez JM; Rosés-Codinachs M; Amaral-Olivera M
    Antimicrob Agents Chemother; 1983 Jul; 24(1):132-3. PubMed ID: 6625552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of Candida spp. of clinical origin to lucknomycin, a new polyenic antibiotic.
    Sousa AS; Gómez-Criado C; Baquero F
    Chemotherapy; 1985; 31(3):211-5. PubMed ID: 3996088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method.
    Espinel-Ingroff A; Arendrup M; Cantón E; Cordoba S; Dannaoui E; García-Rodríguez J; Gonzalez GM; Govender NP; Martin-Mazuelos E; Lackner M; Lass-Flörl C; Linares Sicilia MJ; Rodriguez-Iglesias MA; Pelaez T; Shields RK; Garcia-Effron G; Guinea J; Sanguinetti M; Turnidge J
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates.
    Astvad KMT; Hare RK; Arendrup MC
    Clin Microbiol Infect; 2017 Nov; 23(11):882-887. PubMed ID: 28373148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of MICs of aminocandin for Candida spp. and filamentous fungi.
    Isham N; Ghannoum MA
    J Clin Microbiol; 2006 Dec; 44(12):4342-4. PubMed ID: 17021057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of fluorescent probes to determine MICs of amphotericin B and caspofungin against Candida spp. and Aspergillus spp.
    Peter J; Armstrong D; Lyman CA; Walsh TJ
    J Clin Microbiol; 2005 Aug; 43(8):3788-92. PubMed ID: 16081911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.
    Pfaller MA; Messer SA; Rhomberg PR; Jones RN; Castanheira M
    J Antimicrob Chemother; 2016 Oct; 71(10):2868-73. PubMed ID: 27287236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antifungal activity of farnesyltransferase inhibitors against clinical isolates of Aspergillus and Candida.
    Qiao J; Gao P; Jiang X; Fang H
    Ann Clin Microbiol Antimicrob; 2013 Dec; 12():37. PubMed ID: 24314136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).
    Bartizal K; Gill CJ; Abruzzo GK; Flattery AM; Kong L; Scott PM; Smith JG; Leighton CE; Bouffard A; Dropinski JF; Balkovec J
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2326-32. PubMed ID: 9371328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp.
    Schmitt HJ; Bernard EM; Andrade J; Edwards F; Schmitt B; Armstrong D
    Antimicrob Agents Chemother; 1988 May; 32(5):780-1. PubMed ID: 3134851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
    Singh J; Rimek D; Kappe R
    Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of a new polyene SPK-843 against Candida spp, Cryptococcus neoformans and Aspergillus spp clinical isolates.
    Kantarcioglu AS; Yucel A; Vidotto V
    J Chemother; 2003 Jun; 15(3):296-8. PubMed ID: 12868560
    [No Abstract]   [Full Text] [Related]  

  • 15. Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in
    Espinel-Ingroff A; Turnidge J; Alastruey-Izquierdo A; Botterel F; Canton E; Castro C; Chen YC; Chen Y; Chryssanthou E; Dannaoui E; Garcia-Effron G; Gonzalez GM; Govender NP; Guinea J; Kidd S; Lackner M; Lass-Flörl C; Linares-Sicilia MJ; López-Soria L; Magobo R; Pelaez T; Quindós G; Rodriguez-Iglesia MA; Ruiz MA; Sánchez-Reus F; Sanguinetti M; Shields R; Szweda P; Tortorano A; Wengenack NL; Bramati S; Cavanna C; DeLuca C; Gelmi M; Grancini A; Lombardi G; Meletiadis J; Negri CE; Passera M; Peman J; Prigitano A; Sala E; Tejada M
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of inositol phosphorylceramide synthase by aureobasidin A in Candida and Aspergillus species.
    Zhong W; Jeffries MW; Georgopapadakou NH
    Antimicrob Agents Chemother; 2000 Mar; 44(3):651-3. PubMed ID: 10681333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antifungal activity of 2-(3,4-dimethyl-2,5-dihydro-1H-pyrrol-2-yl)-1-methylethyl pentanoate, a dihydropyrrole derivative.
    Dabur R; Chhillar AK; Yadav V; Kamal PK; Gupta J; Sharma GL
    J Med Microbiol; 2005 Jun; 54(Pt 6):549-552. PubMed ID: 15888463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan.
    Ikeda F; Saika T; Sato Y; Suzuki M; Hasegawa M; Mikawa T; Kobayashi I; Tsuji A
    Med Mycol; 2009 Mar; 47(2):145-8. PubMed ID: 18668422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.
    Pfaller MA; Castanheira M; Messer SA; Jones RN
    Mycoses; 2015 Apr; 58(4):209-14. PubMed ID: 25727853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening the in vitro susceptibility of posaconazole in clinical isolates of Candida spp. and Aspergillus spp. and analyzing the sequence of ERG11 or CYP51A in non-wild-type isolates from China.
    Zhang H; Tan J; Kontoyiannis DP; Zhou Y; Liu W; Zhu P; Shi X; Wan Z; Li R; Liu W
    Diagn Microbiol Infect Dis; 2019 Oct; 95(2):166-170. PubMed ID: 31174994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.